BMAL2 and prostate cancer: Interestingly, a study using metastatic castration‐resistant prostate cancer (mCRPC) organoids derived from patients receiving androgen‐targeting therapies finds that while some AR target genes are significantly down‐regulated, the circadian clock gene BMAL2 is significantly upregulated,29 suggesting that its upregulation is linked to the loss of circadian rhythms in the advanced progression of prostate cancer.